Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p

Autor: François Potus, David Meriwether, Soban Umar, Mohamad Navab, Andrea Iorga, Sébastien Bonnet, Gabriel Wong, Srinivasa T. Reddy, Kaveh Navab, Mansoureh Eghbali, Alan M. Fogelman, Salil Sharma, Steeve Provencher, Sandra Breuils-Bonnet, David J. Ross, Denise Mai
Rok vydání: 2014
Předmět:
Male
Apolipoprotein B
Cardiorespiratory Medicine and Haematology
Inbred C57BL
Cardiovascular
Muscle
Smooth
Vascular

Receptor
IGF Type 1

Rats
Sprague-Dawley

Mice
pulmonary arterial hypertension
Hydroxyeicosatetraenoic Acids
Medicine
Lung
Cells
Cultured

apolipoprotein A-I mimetic peptide 4F
Cultured
biology
Hydroxyeicosatetraenoic acid
Pulmonary
microRNAs
medicine.anatomical_structure
Hypertension
Public Health and Health Services
Muscle
Smooth
medicine.symptom
Cardiology and Cardiovascular Medicine
Receptor
Biotechnology
medicine.medical_specialty
Hypertension
Pulmonary

Cells
Clinical Sciences
Article
Rare Diseases
Physiology (medical)
Internal medicine
Vascular
miR-193
microRNA
Animals
Humans
IGF Type 1
human
Cell Proliferation
Retinoid X Receptor alpha
business.industry
Vascular disease
Cell growth
Hypoxia (medical)
medicine.disease
Pulmonary hypertension
Rats
Mice
Inbred C57BL

lipoproteins
MicroRNAs
Endocrinology
Cardiovascular System & Hematology
biology.protein
Sprague-Dawley
business
Peptides
Zdroj: Circulation, vol 130, iss 9
Popis: Background— Pulmonary arterial hypertension is a chronic lung disease associated with severe pulmonary vascular changes. A pathogenic role of oxidized lipids such as hydroxyeicosatetraenoic and hydroxyoctadecadienoic acids is well established in vascular disease. Apolipoprotein A-I mimetic peptides, including 4F, have been reported to reduce levels of these oxidized lipids and improve vascular disease. However, the role of oxidized lipids in the progression of pulmonary arterial hypertension and the therapeutic action of 4F in pulmonary arterial hypertension are not well established. Methods and Results— We studied 2 different rodent models of pulmonary hypertension (PH): a monocrotaline rat model and a hypoxia mouse model. Plasma levels of hydroxyeicosatetraenoic and hydroxyoctadecadienoic acids were significantly elevated in PH. 4F treatment reduced these levels and rescued preexisting PH in both models. MicroRNA analysis revealed that microRNA-193-3p (miR193) was significantly downregulated in the lung tissue and serum from both patients with pulmonary arterial hypertension and rodents with PH. In vivo miR193 overexpression in the lungs rescued preexisting PH and resulted in downregulation of lipoxygenases and insulin-like growth factor-1 receptor. 4F restored PH-induced miR193 expression via transcription factor retinoid X receptor α. Conclusions— These studies establish the importance of microRNAs as downstream effectors of an apolipoprotein A-I mimetic peptide in the rescue of PH and suggest that treatment with apolipoprotein A-I mimetic peptides or miR193 may have therapeutic value.
Databáze: OpenAIRE